October 31, 2012
Asahi Kasei Pharma announced on October 29 that Asahi Kasei Pharma America, a subsidiary of the company, has begun a global PIII clinical trial for the intravenous anticoagulant ART-123 (thrombomodulin alpha (recombinant); brand name in Japan: Ricomodulin) for the treatment...read more